Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02705547 · ClinicalTrials.gov registry record · Early Phase 1
Rosuvastatin (Crestor) in Friedreich Ataxia
A Early Phase 1 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT02705547: Completed Early Phase 1 study, sponsored by Children's Hospital of Philadelphia.
NCT02705547 is a Early Phase 1 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 12 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02705547, a Early Phase 1 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is an exploratory open-label clinical trial of Rosuvastatin in patients with Friedreich ataxia (FRDA). This is an outpatient trial with the goal of enrolling 10 evaluable adults with genetically confirmed FRDA who are between the ages of 18-65. Subjects will receive 10mg of oral Rosuvastatin daily for three months.
Primary Outcome
Serum ApoA-1 protein levels will be collected at baseline and again at the Week 12 visit.
Interventions
- DRUG Rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-08-04 |
| Phase | Early Phase 1 |
What the finished NCT02705547 record still lists
NCT02705547 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Rosuvastatin is the first listed.
NCT02705547 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02705547 about?
NCT02705547 is a clinical study titled "Rosuvastatin (Crestor) in Friedreich Ataxia". This study is an exploratory open-label clinical trial of Rosuvastatin in patients with Friedreich ataxia (FRDA). This is an outpatient trial with the goal of enrolling 10 evaluable adults with genetically confirmed FRDA who are between the ages of 18-65. Subjects will receive 10mg of oral Rosuvasta...
What is the current status of trial NCT02705547?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2016-05. Estimated completion is 2017-08-04.
What interventions are being tested in trial NCT02705547?
The interventions under investigation include: Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT02705547?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02705547's enrollment target sits among peer trials
12 1530th of 2000 higher than 401 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia